Novel sulfa Schiff bases were synthesized and characterized by a reaction between aromatic sulfonamides and
aromatic aldehydes or heterocyclic ketones in equimolar ratios. Their cytotoxicity was evaluated by the resazurin assay
towards human sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Three of the tested
compounds viz., 4-(anthracen-9-ylmethyleneamino)-N-(pyrimidin-2-yl)benzenesulfonamide (4), 4-(anthracen-9-
ylmethyleneamino)benzenesulfonamide, (5) and 4-((3-phenylallylidene)amino)benzene-sulfonamide, (6) were cytotoxic
(IC50 values: 5.38-19.96 µM). CEM/ADR5000 cells were not cross-resistant to these compounds, indicating activity
against otherwise drug-resistant tumors. Compound 6 inhibited P-glycoprotein by increasing doxorubicin accumulation
and reducing expression of P-glycoprotein in CEM/ADR5000 cells. A human P-glycoprotein homology model was used
for molecular docking studies. Compound 6 and verapamil (a well-known P-glycoprotein inhibitor) docked with similar
binding energies to the same binding pocket.
新型
磺胺Schiff碱通过芳香族磺酰胺与
芳香族醛或杂环酮以等摩尔比例反应合成并表征。其细胞毒性通过对人类敏感的CCRF-C
EM细胞和多药耐药的C
EM/ADR5000白血病细胞进行resazurin测定进行评估。测试的三种化合物,即4-(
蒽9-亚甲基
氨基)-N-(
嘧啶-2-基)苯磺酰胺(4)、4-(
蒽9-亚甲基
氨基)苯磺酰胺(5)和4-((3-苯基烯丙基)
氨基)苯磺酰胺(6)具有细胞毒性(IC50值:5.38-19.96 µM)。C
EM/ADR5000细胞对这些化合物没有交叉耐药性,表明其对其他药物耐药肿瘤仍具有活性。化合物6通过增加
多柔比星的积累并减少C
EM/ADR5000细胞中P-糖蛋白的表达来抑制P-糖蛋白。使用人类P-糖蛋白同源模型进行分子对接研究。化合物6和
维拉帕米(一个著名的P-糖蛋白
抑制剂)与相同结合口袋的结合能相似。